1
|
Zhang J, Lyu J, Wang S, Li M, Liu J, Zhu D, Shi J, Wie J, Zheng X, Feng W. Three New 2,2'-Difurylketone Derivatives and Two New Chromones from the Rehmanniae Radix Praeparata. Chem Biodivers 2021; 18:e2100237. [PMID: 34397144 DOI: 10.1002/cbdv.202100237] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2021] [Accepted: 08/16/2021] [Indexed: 11/10/2022]
Abstract
Rehmanniae Radix Praeparata is the processed products of the root of Rehmannia glutinosa. It has been used as a Traditional Chinese Medicine for thousands of years, and it has been found to possess widely pharmacological activities. In this study, three new 2,2'-difurylketone derivatives (rehmanniaeketone A-C) and two new chromones [3,8-dihydroxy-2-(2-hydroxyethyl)chromone and 3,8-dihydroxy-2-[(2-O-α-D-galactopyranosyloxy)ethyl]chromone] were isolated from the Rehmanniae Radix Praeparata. Furthermore all of the compounds were subjected to cytotoxic testing against the human lung carcinoma A549 cells. The cytotoxic results showed that rehmanniaeketone B and rehmanniaeketone C exhibited more stronger inhibition effects on the cell activity of A549 cells with the IC50 5.23 μM and 2.05 μM than other compounds. And 3,8-dihydroxy-2-(2-hydroxyethyl)chromone exhibited moderately inhibitory activity with the IC50 61 μM. Rehmanniaeketone A and 3,8-dihydroxy-2-[(2-O-α-D-galactopyranosyloxy]chromone showed no inhibitory effects.
Collapse
Affiliation(s)
- Jingke Zhang
- Henan University of Chinese Medicine, Jin Shui Dong Road 156, Zhengzhou, 450046, China.,The Engineering and Technology Center for Chinese Medicine Development of Henan Province, Henan University of Chinese Medicine, Jin Shui Dong Road 156, Zhengzhou, 450046, China
| | - Jinjin Lyu
- Henan University of Chinese Medicine, Jin Shui Dong Road 156, Zhengzhou, 450046, China.,The Engineering and Technology Center for Chinese Medicine Development of Henan Province, Henan University of Chinese Medicine, Jin Shui Dong Road 156, Zhengzhou, 450046, China
| | - Shengchao Wang
- Henan University of Chinese Medicine, Jin Shui Dong Road 156, Zhengzhou, 450046, China.,The Engineering and Technology Center for Chinese Medicine Development of Henan Province, Henan University of Chinese Medicine, Jin Shui Dong Road 156, Zhengzhou, 450046, China
| | - Meng Li
- Henan University of Chinese Medicine, Jin Shui Dong Road 156, Zhengzhou, 450046, China.,The Engineering and Technology Center for Chinese Medicine Development of Henan Province, Henan University of Chinese Medicine, Jin Shui Dong Road 156, Zhengzhou, 450046, China
| | - Juanjuan Liu
- Henan University of Chinese Medicine, Jin Shui Dong Road 156, Zhengzhou, 450046, China.,The Engineering and Technology Center for Chinese Medicine Development of Henan Province, Henan University of Chinese Medicine, Jin Shui Dong Road 156, Zhengzhou, 450046, China
| | - Denghui Zhu
- Henan University of Chinese Medicine, Jin Shui Dong Road 156, Zhengzhou, 450046, China.,The Engineering and Technology Center for Chinese Medicine Development of Henan Province, Henan University of Chinese Medicine, Jin Shui Dong Road 156, Zhengzhou, 450046, China
| | - Jingya Shi
- Henan University of Chinese Medicine, Jin Shui Dong Road 156, Zhengzhou, 450046, China.,The Engineering and Technology Center for Chinese Medicine Development of Henan Province, Henan University of Chinese Medicine, Jin Shui Dong Road 156, Zhengzhou, 450046, China
| | - Junjun Wie
- Henan University of Chinese Medicine, Jin Shui Dong Road 156, Zhengzhou, 450046, China.,The Engineering and Technology Center for Chinese Medicine Development of Henan Province, Henan University of Chinese Medicine, Jin Shui Dong Road 156, Zhengzhou, 450046, China
| | - Xiaoke Zheng
- Henan University of Chinese Medicine, Jin Shui Dong Road 156, Zhengzhou, 450046, China.,The Engineering and Technology Center for Chinese Medicine Development of Henan Province, Henan University of Chinese Medicine, Jin Shui Dong Road 156, Zhengzhou, 450046, China
| | - Weisheng Feng
- Henan University of Chinese Medicine, Jin Shui Dong Road 156, Zhengzhou, 450046, China.,The Engineering and Technology Center for Chinese Medicine Development of Henan Province, Henan University of Chinese Medicine, Jin Shui Dong Road 156, Zhengzhou, 450046, China
| |
Collapse
|
2
|
Yang Q, Zhang Z, Xu H, Ma C. Lidocaine alleviates cytotoxicity-resistance in lung cancer A549/DDP cells via down-regulation of miR-21. Mol Cell Biochem 2019; 456:63-72. [PMID: 30644017 DOI: 10.1007/s11010-018-3490-x] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2018] [Accepted: 12/14/2018] [Indexed: 02/07/2023]
Abstract
Lidocaine (Lido) is a commonly used local anesthetic, which has been reported in various types of cells. However, the effects of Lido on lung cancer cells remain not understood. The study aimed to investigate the underlying mechanisms of Lido in the cisplatin resistance of A549/DDP cells. Different concentrations of cisplatin (0-320 µM) were used to stimulate A549 and A549/DDP cells, and cell viability and apoptosis were examined. To investigate the effect of Lido on A549/DDP cells, the optimum concentration of Lido was selected to treat A549/DDP cells, and cell viability, apoptosis, migration and invasion were then detected. The relative expression of miR-21 in A549/DDP cells or in Lido-treated A549/DDP cells was analyzed by RT-qPCR. MiR-21 mimic, inhibitor and its control were transfected into A549/DDP cells to explore the regulatory effect of miR-21 on the cisplatin resistance in A549 or A549/DDP cells. The effects of miR-21 on PTEN/PI3K/AKT and PDCD4/JNK pathways were detected by western blot. The cisplatin resistance of A549/DDP cells was higher than that of A549 cells. Lido significantly suppressed cell viability, induced apoptosis, and inhibited cell migration and invasion in A549/DDP cells. Additionally, miR-21 expression in A549/DDP was higher than that in A549 cells, and Lido significantly down-regulated miR-21 expression in A549/DDP cells. MmiR-21 inhibition exhibited the same effects as Lido on the cisplatin resistance of A549/DDP cells. Further, miR-21 suppression regulated PTEN/PI3K/AKT and PDCD4/JNK pathways in A549/DDP cells. These findings indicated that Lido alleviated the cytotoxicity resistance of A549/DDP cells via down-regulation of miR-21.
Collapse
Affiliation(s)
- Qing Yang
- Department of Anesthesiology, Huaihe Hospital of Henan University, No. 8, Baobei Road, Gulou District, Kaifeng, 475000, China
| | - Zhi Zhang
- Department of Anesthesiology, Huaihe Hospital of Henan University, No. 8, Baobei Road, Gulou District, Kaifeng, 475000, China
| | - Haixia Xu
- Department of Anesthesiology, Huaihe Hospital of Henan University, No. 8, Baobei Road, Gulou District, Kaifeng, 475000, China.
| | - Chuangen Ma
- Department of Anesthesiology, Huaihe Hospital of Henan University, No. 8, Baobei Road, Gulou District, Kaifeng, 475000, China.
| |
Collapse
|
3
|
Bauml J, Haas A, Simone CB, Li SQ, Cohen RB, Langer CJ, Mao JJ. Acupuncture for Dyspnea in Lung Cancer: Results of a Feasibility Trial. Integr Cancer Ther 2016; 15:326-32. [PMID: 27114385 PMCID: PMC5739187 DOI: 10.1177/1534735415624138] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
Purpose. Dyspnea is a common and distressing symptom for patients with lung cancer (LC) because of disease burden, therapy toxicity, and comorbid illnesses. Acupuncture is a centuries-old therapy with biological plausibility for relief of dyspnea in this setting. This pilot study aimed to evaluate the feasibility and preliminary effectiveness of acupuncture for dyspnea among patients with LC. Methods. Eligible patients had a diagnosis of LC and clinically significant dyspnea without a clear organic cause. The treatment consisted of 10 weekly acupuncture sessions, with a follow-up visit 4 weeks after therapy. The primary outcome was dyspnea severity as measured using a validated Numerical Rating Scale (NRS) of 0 to 10 (10 being “most severe shortness of breath imaginable”). Results. We enrolled 12 patients in the study. The median age was 64.5 years; 66.7% of the patients were female, and 66.7% were Caucasians. Among those enrolled, 10 (83.3%) were able to complete all 10 acupuncture sessions. Acupuncture was well tolerated; adverse events were mild and self-limited. Mean (SD) dyspnea scores on the NRS improved from 6.3 (1.7) at baseline to 3.6 (1.9; P = .003) at the end of treatment and 3.2 (2.3; P = .008) at follow-up. Fatigue and quality of life also improved significantly with acupuncture (P < .05). Conclusion. Among patients with LC, acupuncture was well tolerated and exhibited promising preliminary beneficial effects in the treatment of dyspnea, fatigue, and quality of life. Performing a trial in this population appears feasible.
Collapse
Affiliation(s)
- Joshua Bauml
- Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| | - Andrew Haas
- Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA Division of Pulmonary, Allergy and Critical Care, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| | - Charles B Simone
- Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| | - Susan Q Li
- Department of Family Medicine and Community Health, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| | - Roger B Cohen
- Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| | - Corey J Langer
- Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| | - Jun J Mao
- Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA Department of Family Medicine and Community Health, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
4
|
Mehiri S, Oulmoudne N, Revault C, Mornex F. Gestion des situations difficiles lors de l’irradiation : toux, dyspnée et hémoptysie. Cancer Radiother 2013; 17:538-42. [DOI: 10.1016/j.canrad.2013.07.140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2013] [Accepted: 07/10/2013] [Indexed: 10/26/2022]
|
5
|
Abstracts. Br J Occup Ther 2013. [DOI: 10.1177/03080226130767s101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
6
|
|
7
|
Abstract
OBJECTIVES To present a clinical update regarding common distressing lung cancer symptoms and provide an update on management interventions. DATA SOURCES Journal articles, systematic reviews. CONCLUSION Goals of treatment of the patient with lung cancer must include management of the high symptom burden that often accompanies the disease. IMPLICATIONS FOR NURSING PRACTICE Early assessment and management of symptoms improves quality of life. Nurses play a key role in implementing and monitoring these interventions.
Collapse
Affiliation(s)
- Maureen Huhmann
- Department of Nutritional Sciences, University of Medicine and Dentistry of New Jersey, Newark, NJ, USA.
| | | |
Collapse
|
8
|
Quinn-Lee L, Moch SD, Mabin J, Davey S, Davis L, Williams K, Gianlupi A, Weggel J. Use of oxygen at the end of life: on what basis are decisions made? Int J Palliat Nurs 2012; 18:369-70, 372. [DOI: 10.12968/ijpn.2012.18.8.369] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | | | | | | | | | - Kelsey Williams
- University of Wisconsin-Eau Claire, 105 Garfield Avenue, Eau Claire, WI, 54702642, USA
| | - Adriane Gianlupi
- Pulmonary/Critical Care Medicine, Marshfield Clinic, Eau Claire Center, WI
| | | |
Collapse
|
9
|
Gay EB, Weiss SP, Nelson JE. Integrating palliative care with intensive care for critically ill patients with lung cancer. Ann Intensive Care 2012; 2:3. [PMID: 22339793 PMCID: PMC3306209 DOI: 10.1186/2110-5820-2-3] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2011] [Accepted: 02/16/2012] [Indexed: 01/22/2023] Open
Abstract
With newer information indicating more favorable outcomes of intensive care therapy for lung cancer patients, intensivists increasingly are willing to initiate an aggressive trial of this therapy. Concerns remain, however, that the experience of the intensive care unit for patients with lung cancer and their families often may be distressing. Regardless of prognosis, all patients with critical illness should receive high-quality palliative care, including symptom control, communication about appropriate care goals, and support for both patient and family throughout the illness trajectory. In this article, we suggest strategies for integrating palliative care with intensive care for critically ill lung cancer patients. We address assessment and management of symptoms, knowledge and skill needed for effective communication, and interdisciplinary collaboration for patient and family support. We review the role of expert consultants in providing palliative care in the intensive care unit, while highlighting the responsibility of all critical care clinicians to address basic palliative care needs of patients and their families.
Collapse
Affiliation(s)
- Elizabeth B Gay
- Department of Pulmonary and Critical Care Medicine, University of Virginia Health Systems, Charlottesville, VA
| | - Stefanie P Weiss
- Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, Mount Sinai School of Medicine, New York, NY
| | - Judith E Nelson
- Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, Mount Sinai School of Medicine, New York, NY
| |
Collapse
|
10
|
Applicability and generalizability of palliative interventions for dyspnoea: one size fits all, some or none? Curr Opin Support Palliat Care 2011; 5:92-100. [DOI: 10.1097/spc.0b013e328345d4a1] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
11
|
Abstract
Dyspnea, nausea and vomiting, anorexia, fatigue, and sleep disturbances are common and distressing in advanced cancer. We updated previous systematic reviews of how these symptoms can be alleviated with targeted literature searches. The approach to these symptoms requires comprehensive symptom assessment; treating underlying causes when benefits exceed risks; prioritizing treatment, as patients usually have many symptoms; and addressing psychosocial and spiritual distress. For dyspnea, evidence supports systemic opioids and nonpharmacological treatments such as a fan. The strongest evidence supports metoclopramide for cancer-related nausea and octreotide for bowel obstruction. For anorexia, enteral or parenteral nutrition is indicated with obstruction and expected prognosis of at least 6 weeks. Evidence supports several drugs for appetite affecting quality of life. For fatigue, evidence supports psychosocial interventions and methylphenidate. For insomnia, evidence supports cognitive-behavioral therapy in cancer; no sleep agents have superior effectiveness.
Collapse
|